Sénéchal Mario, LePrince Pascal, Tezenas du Montcel Sophie, Bonnet Nicolas, Dubois Michelle, El-Serafi Mohamed, Ghossoub J J, Pavie Alain, Gandjbakhch Iradj, Dorent Richard
Service de Chirurgie Cardio-Vasculaire et Thoracique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
J Heart Lung Transplant. 2004 Feb;23(2):165-70. doi: 10.1016/S1053-2498(03)00104-9.
The incidence of mediastinitis after heart transplantation has been reported to be between 2.5% and 7.5%. Most previous reports from the transplant literature have assessed patients who had not received induction therapy.
From December 1996 to January 2002, a total of 230 heart transplants were performed using induction therapy with rabbit anti-thymocyte globulin at La Pitié Salpêtrière Hospital (Paris, France). Mediastinitis developed in 15 patients (6.5%). A case-control study was performed to characterize the clinical presentation, microbiology, risk factors and therapy of mediastinitis after heart transplantation.
Only 4 patients (26%) had a temperature of >38 degrees C and 6 patients (40%) had a white blood cell count of >10,000 cells/mm(3). Septicemia (46%) and positive temporary epicardial pacing wires culture (60%) were frequently observed. Staphylococcus aureus (5 of 15), Staphylococcus epidermidis (5 of 15) and gram-negative bacteria (5 of 15) were the causative organisms cultured intra-operatively. Mean duration of mechanical ventilation (2.4 vs 1.6 days; p < 0.03) and use of ventricular assistance (20% vs 0%; p < 0.04) were different between cases and controls. The mortality rate at hospital discharge was 6.7% (1 of 15).
In the context of immunosuppression after heart transplantation, a high degree of suspicion is necessary to make the diagnosis of mediastinitis. Positive blood and temporary epicardial pacing wires cultures can be helpful in suggesting the presence of mediastinitis. Using vancomycin and an aminoglycoside as prophylaxis has to be considered because of the high prevalence of methilcilin-resistant S epidermidis and gram-negative bacteria. Conservative therapy (sternal debridement without muscle flap closure, and closed-chest drainage) showed excellent results in this series.
据报道,心脏移植后纵隔炎的发生率在2.5%至7.5%之间。移植文献中以前的大多数报告评估的是未接受诱导治疗的患者。
1996年12月至2002年1月,法国巴黎皮提耶尔-萨尔佩特里埃医院共进行了230例心脏移植手术,采用兔抗胸腺细胞球蛋白进行诱导治疗。15例患者(6.5%)发生了纵隔炎。进行了一项病例对照研究,以描述心脏移植后纵隔炎的临床表现、微生物学、危险因素和治疗方法。
只有4例患者(26%)体温高于38摄氏度,6例患者(40%)白细胞计数高于10000个细胞/mm³。经常观察到败血症(46%)和临时心外膜起搏导线培养阳性(60%)。术中培养出的致病微生物为金黄色葡萄球菌(15例中的5例)、表皮葡萄球菌(15例中的5例)和革兰氏阴性菌(15例中的5例)。病例组和对照组之间的机械通气平均持续时间(2.4天对1.6天;p<0.03)和心室辅助的使用情况(20%对0%;p<0.04)有所不同。出院时的死亡率为6.7%(15例中的1例)。
在心脏移植后的免疫抑制情况下,高度怀疑对于纵隔炎的诊断是必要的。血培养和临时心外膜起搏导线培养阳性有助于提示纵隔炎的存在。由于耐甲氧西林表皮葡萄球菌和革兰氏阴性菌的高流行率,必须考虑使用万古霉素和氨基糖苷类药物进行预防。在本系列研究中,保守治疗(不进行肌瓣闭合的胸骨清创术和闭式胸腔引流)显示出了优异的效果。